๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Response to Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myelogenous Leukemia Relapsing in Chronic and Advanced Phase Following Allogeneic Hematopoietic Stem Cell Transplantation

โœ Scribed by Matthew P. Wright; John D. Shepherd; Michael J. Barnett; Stephen H. Nantel; Heather J. Sutherland; Cynthia L. Toze; Donna E. Hogge; Thomas J. Nevill; Kevin W. Song; Yasser R. Abou Mourad; Sujaatha Narayanan; Maryse M. Power; Clayton A. Smith; Donna L. Forrest


Book ID
116281238
Publisher
Elsevier Science
Year
2010
Tongue
English
Weight
201 KB
Volume
16
Category
Article
ISSN
1083-8791

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Novel tyrosine kinase inhibitor therapy
โœ Elias Jabbour; Jorge Cortes; Hagop Kantarjian; Sergio Giralt; Borje S. Andersson ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 72 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND. Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML) are increasingly likely to have received a novel tyrosine kinase inhibitor (NTKI) after failing imatinib mesylate. It is unknown whether the use of these NTKI